Table 1.

Details of six cases of uveitic cystoid macular edema treated with nepafenac 0.1%

Case	Previous treatment	Length of previous treatment	Pre-treatment retinal thickness (μm)	Post-treatment retinal thickness (μm)	Retinal thickness improvement (μm)	Pre-treatment VA (logMAR VA)	Post-treatment VA (logMAR VA)	VA improvement (logMAR)	Treatment
#1	ketorolac + prednisolone	8 months	695	164	531	20/80 (0.60)	20/20 (0)	0.60	Nepafenac 0.1% TID 3 months
#2 OD	ketorolac + prednisolone	6 months	465	207	258	20/60 − 1 (0.50)	20/20 (0)	0.50	Nepafenac 0.1% TID 6 months
#2 OS	ketorolac + prednisolone	6 months	443	179	264	20/60 − 1 (0.50)	20/20 (0)	0.50	Nepafenac 0.1% TID 6 months
#3	prednisolone	>3 years	315	204	111	20/40 (0.30)	20/25 (0.10)	0.20	Nepafenac 0.1% TID and prednisolone acetate 1% QID 11 weeks
#4	none	not applicable	365	254	111	20/100 (0.70)	20/80 + 1 (0.58)	0.12	Nepafenac 0.1% TID and prednisolone acetate 1% TID 6 + weeks
#5	ketorolac + prednisolone	2 months	371	284	87	20/50 −1 (0.42)	20/30 (0.18)	0.24	Nepafenac 0.1% and prednisolone acetate 1% TID 12 + weeks
Total mean data ± SD			442 ± 135.4	215 ± 45.5	227 ± 168.1	0.50 ± 0.14	0.14 ± 0.23	0.36 ± 0.20

Abbreviations: QID, four times daily; SD, standard deviation; TID, three times daily; VA, visual acuity.